chereby can ify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office, Box Sequence

P.O. Box 2327, Arlington, VA 22202 on:

David R. Saliwanchik, Patent Attorney

AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c) Examining Group 1638 Patent Application Docket No. SPO-115C1 Serial No. 09/888,035

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Cynthia E. Collins

Art Unit

1641

Applicant(s)

Atsunori Fukuda, Yoshiyuki Tanaka

Serial No.

09/888,035

Filed

June 22, 2001

Conf. No.

9222

For

Sodium/Proton Antiporter Gene

Assistant Commissioner for Patents U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

## AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows:

## In the Specification

Please replace existing pages 1-6 of the Sequence Listing with new pages 1-7.